clinical trial · NCT07652164
Water Vapor Ablation for Grade Group 3 Prostate Cancer
Francis Medical Inc.·N/A·not yet recruiting·n = 120
Prostate CancerWater Vapor Ablation
brief summary
The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer. Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.
started
Aug 31, 2026
primary completion
Aug 1, 2028
completion
Sep 1, 2028
last updated
Aug 11, 2026
official title
Vanquish® Water Vapor Ablation for Grade Group 3 PrOstate CanceR: A Multicenter Single Arm Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol